MiMedx Group (NASDAQ:MDXG) Research Coverage Started at Lake Street Capital

Lake Street Capital started coverage on shares of MiMedx Group (NASDAQ:MDXGFree Report) in a report released on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $12.00 price objective on the stock.

Separately, Mizuho boosted their price objective on shares of MiMedx Group from $13.00 to $14.00 and gave the company a buy rating in a research report on Friday, March 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Buy and an average price target of $12.25.

Read Our Latest Research Report on MDXG

MiMedx Group Stock Up 1.0 %

Shares of MiMedx Group stock opened at $8.15 on Thursday. The company has a current ratio of 3.57, a quick ratio of 3.11 and a debt-to-equity ratio of 0.34. The company’s fifty day simple moving average is $8.10 and its two-hundred day simple moving average is $7.65. The company has a market cap of $1.20 billion, a P/E ratio of 25.47 and a beta of 1.34. MiMedx Group has a 12-month low of $3.08 and a 12-month high of $9.27.

Insider Transactions at MiMedx Group

In related news, COO Ricci S. Whitlow sold 15,271 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total transaction of $122,320.71. Following the sale, the chief operating officer now directly owns 401,050 shares of the company’s stock, valued at approximately $3,212,410.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Ricci S. Whitlow sold 15,493 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $8.07, for a total transaction of $125,028.51. Following the sale, the chief operating officer now directly owns 416,321 shares of the company’s stock, valued at approximately $3,359,710.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Ricci S. Whitlow sold 15,271 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total transaction of $122,320.71. Following the sale, the chief operating officer now directly owns 401,050 shares in the company, valued at $3,212,410.50. The disclosure for this sale can be found here. Insiders own 19.90% of the company’s stock.

Institutional Trading of MiMedx Group

A number of institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP purchased a new stake in shares of MiMedx Group during the 4th quarter valued at about $999,000. Optimist Retirement Group LLC purchased a new stake in shares of MiMedx Group during the 4th quarter valued at about $177,000. GSA Capital Partners LLP purchased a new stake in shares of MiMedx Group during the 4th quarter valued at about $264,000. Legal & General Group Plc boosted its holdings in shares of MiMedx Group by 1.3% during the 4th quarter. Legal & General Group Plc now owns 113,552 shares of the company’s stock valued at $996,000 after acquiring an additional 1,495 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of MiMedx Group by 372,491.9% during the 4th quarter. Barclays PLC now owns 275,718 shares of the company’s stock valued at $2,418,000 after acquiring an additional 275,644 shares during the last quarter. Hedge funds and other institutional investors own 43.85% of the company’s stock.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

Featured Stories

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.